Has the perception of disability among COPD patients applying for pension changed during the last 20 years?  by RINGBÆK, T. & VISKUM, K.
Has the perception of disability among COPD
patients applying for pension changed during
the last 20 years?
T. RINGBÆK* AND K. VISKUM{
*Department of Pulmonary Medicine, University Hospital of Copenhagen, Hvidovre and {Department of
Pulmonary Medicine, University Hospital of Copenhagen, Gentofte, Denmark
The aim is to examine the change in lung function, treatment and pulmonary symptoms in patients with chronic
obstructive pulmonary disease (COPD) or chronic bronchitis (CB) applying for a pension during the period 1977–
1996. In addition, we compared the perception of disability in males and females.
From 1977 to 1996, 947 patients with COPD or CB were evaluated for obtaining economic support due to
disability. In order to test the trend, the patients were divided into three periods: (1) 1977–1983, (2) 1984–1989 and
(3) 1990–1996.
Compared to females, males had substantial more pack-years of smoking (36 vs. 28, P50?001), but their FEV1
was only slightly decreased (46?9% versus 49?6% predicted, P=0?047). Females reported significantly more often
attacks of dyspnoea [OR: 1?5(1?00–2?2)] and any kind of dyspnoea during daytime [OR: 4?0(1?2–13?3)]. From
period 1 to period 3, FEV1 increased significantly (45–53% predicted, P50?001). Despite the increased FEV1, the
use of inhaled corticosteroid had increased markedly (9–32% of the patients, P50?001). The results did not change
when patients with asthma were included.
Our data suggest that both sexes, especially females, have become more aware of pulmonary symptoms and tend
to react to them more actively by demanding evaluation and treatment.
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Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality (1,2). In Europe,
mortality rates of COPD in Danish males and females
rank second highest and highest, respectively (3). Generally,
the morbidity is expressed as hospital admissions, out-
patients services, consumption of medicine and sickness
absence, whereas early retirement due to disability has only
been addressed in few studies (4–9).
The study examines the association of impaired lung
function in patients with COPD or chronic bronchitis and
the request for early retirement in the period 1977–1996,
inclusively. In addition, the change in treatment and
pulmonary symptoms in patients applying for a pension
during the last 20 years was examined.Received 8 August 2000 and accepted in revised form 13 February
2001.
Correspondence should be addressed to: Thomas Ringbaek,
Moseskraenten 17, DK-3140 Aalsgaarde, Denmark. E-mail:
ringbaek@dadlnet.dk
0954-6111/01/050398+06 $35?00/0Several studies suggest that females are more susceptible
to tobacco smoke and are reporting more lung symptoms
than smoking males (10,11). In this study, we tested this
hypothesis by comparing the perception of disability in
males and females.
Methods
From 1977 to 1996 approximately 2200 patients with
pulmonary symptoms were referred to two specialists in
pulmonary medicine (T.H. and K.V.) for medical evalua-
tion for economic support due to disability. In 947 cases,
COPD and chronic bronchitis were diagnosed according to
international guidelines (12). In order to avoid misinter-
pretation from misclassification of asthma, we made the
same analyses when patients with asthma (296) were
included, and examined whether this changed our results.
Excluded were patients with actual cancer, previous
pulmonary resection, ciliary dyskinesia, bronchiectasis,
cystic fibrosis, a1-anti-trypsin deficiency, actual or previous
pulmonary tuberculosis or pneumothorax. Information
on pulmonary symptoms was interview administered:# 2001 HARCOURT PUBLISHERS LTD
PERCEPTION OF DISABILITY AMONG COPD PATIENTS 399dyspnoea during daytime, during night-time or during
exercise, attacks of dyspnoea or dyspnoea at rest, and
coughing. All patients had forced expiratory volume in 1 sec
(FEV1) and forced vital capacity (FVC) measured with a
vitalograph. In selected cases a reversibility test was
performed (48?2%). In these cases the best FEV1 and
FVC have been used. ‘FEV1% of predicted value’ was
calculated from reference values given by the Danish Lung
Association (13). The number of package years of tobacco
was calculated (1 cigarette=1 g, 1 cheroot= 3?5 g, 1
cigar=5 g, pipe tobacco: actual number of grams). Patients
gave information on actual alcohol consumption, and they
were classified with a positive alcohol history if they had
ever been treated with disulfiram, had been hospitalized due
to abuse of alcohol or had any family catastrophes related
to alcohol. As ischaemic heart disease is a frequent
contributor of pulmonary symptoms in tobacco smokers,
this disease has been reported as well. In order to test the
trend, the patients were divided into three periods: (1)
1977–1983, (2) 1984–1989 and (3) 1990–1996.
Information concerning the result of the application for
benefits is restricted and was not available to the authors.
STATISTICS
Data analysis and descriptive statistics were performed with
the Statistical Package for Social Sciences (SPSS) version.
8.0. The binominal test, chi-squared, two sample t-tests and
Mann–Whitney were used as appropriate to compare the
differences between the groups. A multiple regression
analysis was undertaken to examine whether gender or
diagnosis was a determinant of pulmonary symptoms.
Entered variables are listed in Table 1. A two-sided P-value
50?05 was considered significant.
Results
During the last 20 years, a little more than half of the
patients were males, and most were still smoking and had
chronic bronchitis (Table 2). Mild COPD with an FEV1
460% of predicted value was seen in 258 (27?2%) of the
patients, and 78 (8?2%) had ‘only’ chronic bronchitis (CB)
with a FEV1480%. However, although the females had
significantly less pack-years of smoking, they had the same
degree of lost FEV1. Abuse of alcohol was significantly
more common in males as compared with females. When
the 296 patients with asthma were included, all differences
between the two genders remained unchanged (data not
shown).
When adjusted for clinical parameters and time of
entrance, females reported significantly more often dys-
pnoea during exercise [2?5(1?1–5?6)], dyspnoea while resting
[2?6(1?2–5?5)] and any kind of dyspnoea during daytime
[2?9(1?2–6?8)] (Table 3). In addition, females tended to have
more attacks of dyspnoea and nocturnal dyspnoea, and
when patients with asthma were included, this difference in
gender became significant.
Although, bronchodilators are regarded as the corner-
stone of symptomatic treatment, only 65?3% of the patientswere using bronchodilators. Inhaled and systemic corticos-
teroid had only been prescribed to a minority of the
patients (Table 2). Compared with males, females were
more often using inhaled corticosteroid and bronchodila-
tors, especially b2-agonists.
THE TREND OF PULMONARY DISABILITY
IN PATIENTS SEEKING FINANCIAL
SUPPORT
The percentage of females had been increasing (Table 1).
Mean FEV1 increased markedly from 45% to 53% of
predicted value. During the 20-year period, frequency of
attacks of dyspnoea, dyspnoea during night-time and
‘without any dyspnoea during daytime’ had nearly doubled,
while the frequency of dyspnoea on effort had decreased.
No change was seen in the frequency of dyspnoea at rest.
Use of theophylline had become more rare, and a
comparable increase in the use of b2-agonists and anti-
cholinergica had been reported. The use of inhaled
corticosteroid had increased markedly. The increase in
FEV1 and use of inhaled steroids referred were of equal size
for men and women.
When patients with asthma were included, exactly the
same trend was observed. Fewer patients were current
smokers and correspondingly fewer patients had chronic
bronchitis.
Discussion
In clients applying for pension, during a 20-year period,
lung function and prescribed asthma medication have
increased and the pattern of symptoms has changed.
Nocturnal dyspnoea and attacks of dyspnoea have in-
creased while dyspnoea during exercise and ‘any kind of
dyspnoea during daytime’ have decreased. It is the
impression that the perception of disease has changed
during the period. The population has become more aware
of symptoms and tends to react to them more actively by
demanding evaluation and treatment. In addition, the study
has shown that compared with men, women were reporting
more dyspnoea in spite of a higher FEV1% predicted and a
lower consumption of tobacco.
In the period 1977–1996 inclusively the total number of
persons applying for disablement benefits is not known.
The geographic area from which medical evaluation for
pension was requested in this study was mainly the
Municipality of Copenhagen, but requests from neighbour-
ing municipalities were not uncommon. Due to the above-
mentioned reservations, this is not an epidemiological study
of persons applying for benefits due to lung disease.
However, due to the number involved, the trends observed
are considered representative for the period.
During the period of the study decision-making became
increasingly decentralized. This may have reduced the
number of specialist evaluations, probably of the persons
with the most marked symptoms and reduction of
lung function. The criteria for an early pension and
TABLE 1. Changes in basic characteristic, lung function, pulmonary symptoms and medication from 1977 to 1996. Presented for patients with COPD/chronic bronchitis and
when patients with asthma are included
COPD and chronic bronchitis Asthma included
Group 1
1997–1983
Group 2
1984–1989
Group 3
1990–1996
Difference between
group 1 and group 3
P-value/mean
(95%-CI)
Group 1
1977–1983
Group 3
1990–1996
Difference between
group 1 and group 3
P-value/mean
(95%-CI)
Number 377 324 246 50?001 484 330 50?001
Males (%) 58?9 57?4 50?8 0?047 53?7 47?0 0?06
Age (years) 55?8 56?8 56?1 0?3 (71?0–1?6) 54?0 53?3 0?7 (70?6–2?0)
Body mass index (kgm72) 24?5 25?6 25?6 1?1 (0?2–2?1) 24?8 25?6 0?8 (70?04–1?5)
Current smokers (%) 77?5 71?8 69?1 0?02 71?0 63?5 0?026
Pack-years of smoking (years) 32 33 30 0?90 30 27 0?47
FEV1 (% of predicted value) 44?8 48?1 53?0 8?2 (4?8–11?5) 48?6 58?7 10?1 (7?0–13?3)
Ischaemic heart disease (%) 5?8 8?6 8?5 0?19 5?2 6?7 0?37
Cor pulmonale (%) 5?3 4?0 2?8 0?14 4?3 2?4 0?15
Chronic bronchitis (%) 87?3 88?3 78?9 0?005 71?9 62?4 0?004
Dyspnoea during daytime:
Attacks (%) 14?1 13?6 22?4 0?007 28?9 37?9 0?007
During exercise (%) 97?9 93?8 93?5 0?005 95?9 89?4 50?001
At rest (%) 5?0 5?2 4?9 0?93 5?6 5?2 0?79
‘Without dyspnoea’ (%) 1?9 5?6 6?1 0?012 1?7 4?5 0?014
Dyspnoea during night-time (%) 11?7 12?0 19?9 0?005 20?2 27?9 0?012
Medication:
b2-agonist (%) 49?7 54?3 62?3 0?002 57?1 69?8 50?001
Anti-cholinergica (%) 4?5 9?6 9?4 0?015 5?0 9?8 0?008
Theophylline (%) 35?4 25?6 16?8 50?001 39?5 19?8 50?001
‘Without bronchodilator’ (%) 33?0 38?6 32?4 0?88 26?5 25?9 0?85
Inhaled glucosteroid (%) 9?0 17?3 33?4 50?001 17?0 43?6 50?001
Systemic glucosteroid (%) 5?3 4?9 7?4 0?30 8?3 8?2 0?98
CI: Confidence interval.
Continuous variables are presented as mean except ‘pack-years’ which is presented as median.
400
T
.
R
IN
G
B
Æ
K
A
N
D
K
.
V
IS
K
U
M
TABLE 2. Characteristics of patients requesting financial support due to pulmonary symptoms from COPD/chronic bronchitis.
Males and females are compared
Missing M/F Male Female
P-value/difference
mean (95% CI)
Number 0/0 533 414 50?001
Age (years) 0/0 57?4 (8?8) 54?7 (7?1) 2?7 (1?6–3?7)
Body mass index (BMI) (kgm72) 12/3 26?0 (5?5) 24?1 (5?7) 1?8( 1?1–2?6)
Chronic bronchitis (%) 0/0 84?4 86?7 0?32
Current smokers (%) 0/1 74?9 71?4 0?24
Pack-years of smoking (years) 17/14 36 (0–99) 28 (0–75) 50?001
FEV1 (% of predicted value) 4/0 46?9 (20?9) 49?6 (20?5) 2?7 (0?04–5?4)
FEV1/FVC (%) 5/0 53?6 (15?5) 56?7 (15?9) 3?1 (1?1–5?1)
Ischaemic heart disease (%) 0/0 10?5 36 50?001
Cor pulmonale (%) 0/0 4?5 3?9 0?63
Positive alcohol history (%) 0/0 19?7 7?2 50?001
Abuse of alcohol at present* (%) 14/22 25?4 8?7 50?001
Inhaled glucosteroid (%) 2/1 13?7 23?2 50?001
Systemic glucosteroid (%) 2/1 6?2 5?1 0?46
b2 -agonist (%) 2/1 50?3 60?0 0?003
Anti-cholinergica (%) 2/1 7?2 8?0 0?63
Theophylline (%) 2/1 26?6 31?2 0?11
Without bronchodilator (%) 2/1 39?7 28?3 50?001
M: male; F: female; CI: confidence interval.
Continuous variables are presented as mean (SD) except ‘pack-years’ which is presented as median (range). SD and range are
only presented for COPD/chronic bronchitis.
*Consumption of alcohol exceeding the recommendation in Denmark (males: 521 drinks week71; females: 514 drinks
week71).
TABLE 3. The influence of gender on pulmonary symptoms. Calculation of odds ratios (OR) for females when adjusted for
clinical parameters and time of entrance, and when misclassification of COPD as asthma was taken into account
Patients with COPD/
chronic bronchitis (n=947)
OR (95% CI)
Patients with asthma
included (n=1243)
OR (95% CI)
Mucus hyper-secretion 1?2 (0?8–1?9) 1?3 (0?9–1?8)
Dyspnoea during exercise 2?5 (1?1–5?6) 2?9 (1?6–5?0)
Attacks of dyspnoea 1?4 (0?96–2?1) 1?4 (1?02–1?9)
Dyspnoea at rest 2?6 (1?2–5?5) 1?9 (1?1–3?5)
Any dyspnoea during daytime 2?9 (1?2–6?8) 3?8 (1?7–8?4)
Nocturnal dyspnoea 1?3 (0?8–1?9) 1?4 (1?04–2?0)
Clinical variables: age (1 year) forced expiratory volume in 1 sec (1% of predicted) pack-years of smoking (1 year); smoking
habits (never smoker/ex-smoker/light smoker 1–14 g day71; heavy smoker 15 g day71) body mass index (518, 18–24?9, 25–
29?9, 30 kgm72); history of alcoholism (yes/no); ischaemic heart disease (yes/no); cor pulmonale (yes/no). Time of entrance:
group 1=1977–1983; group 2=1984–1989; group 3=1990–1996.
CI: confidence interval.
PERCEPTION OF DISABILITY AMONG COPD PATIENTS 401disability pension have remained the same during the study
period.
In the 1980s and 1990s unemployment was high in
Denmark. This may have influenced a number of persons
with a feeling of disability due to pulmonary disease toseek disablement pension. This may be another explanation
for the better lung function in the last two periods
described.
The risk of misclassification of COPD and asthma is well
known. When patients with asthma were included in our
402 T. RINGBÆK AND K. VISKUManalyses, very small changes were observed. Misclassifica-
tion between COPD and other diagnoses cannot be ruled
out, but this is less common, and therefore only a minor
potential source of error.
A comparison of our results and COPD patients from a
population study in Oslo from 1973 to 1974 shows that,
despite a lower FEV1, our patients had less dyspnoea (9). In
the Norwegian study, 21% of the patients reported
dyspnoea at rest and 58% reported attacks of dyspnoea.
Surprisingly, they found a higher proportion of females
(60%), and these were reporting more pulmonary symp-
toms than the males. However, this may only explain a
minor part of the difference between the two studies.
Another explanation for the differences in symptoms of
COPD cases in Oslo and those seeking pension in our study
could be that the data in Oslo was collected using a
questionnaire filled out by the patient while the data in the
present study was collected by physicians in interview. The
latter method may reduce the patient readiness to report
symptoms.
MEDICATION
The use of most types of asthma medicine increased during
the period following the trend seen in Denmark for patients
with obstructive lung disease—asthma as well as COPD.
Similarly, increased rate of inhaled adrenergic bronchodi-
lator prescriptions and decreased issuance of xanthines
have been observed in the U.S. (14). In our study, the
increased frequency of patients with dyspnoea could
explain some of the increase in use of inhaled steroids
and bronchodilators. However, the beneficial effect of
steroids in COPD patients is uncertain. Until recently, an
objective response to inhaled or oral corticosteroid has
justified treatment with inhaled corticosteroid (15). Recent
controlled studies have concluded that use of inhaled
steroid is of no or limited value in COPD (16,17).
GENDER
The smoking habits in Denmark have changed. Since the
beginning of the 1950s the frequency of smoking among
males has declined steadily from nearly 80% to 40%,
whereas the frequency among females has been fairly stable
around 40%. The increase in the percentage of women
among applicants for pension could be explained by a
higher susceptibility to the ill-effects of smoking (10,11,18),
and the long period of latency before signs of disease.
Women started smoking in Denmark in the 1940s. Both our
study, the Lung Health Study and the PAARC ‘Pollution
Atmosphe´rique et Affections Respiratories Chroniques’
population-based survey found that compared with men,
women were reporting more dyspnoea in spite of the same
age, FEV1 and a lower consumption of tobacco (19,20). In
two large population studies, after adjusting for smoking,
females had an increased risk of hospitalization for COPD
(21). Several studies suggest that more females than males
perceive disability. In a population study of 876 subjects,
increased perception of respiratory symptoms after metha-choline-induced bronchoconstriction was shown in females
(22). Studying 1458 elderly subjects, Merrill et al. found
that more women than men reported disability and
functional limitation (23). Although FEV1% is a good
predictor of breathlessness, other indexes of lung function
impairment contribute. The above-mentioned studies in-
cluding ours have not adjusted for diffusion capacity or
arterial gas tensions. However, we have included clinical
signs of cor pulmonale, which to some extent reflects a low
arterial oxygen tension.
Conclusion
Our data of selected patients suggest that both sexes, but
especially females, have become more aware of pulmonary
symptoms from COPD and asthma, and tend to react to
them more actively by demanding evaluation and treat-
ment. This has to be confirmed in larger population studies.
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